Callio Therapeutics Initiates First-in-Human Trial of Dual-Payload ADC CLIO-8221 for HER2-Positive Solid Tumors
Key Insights
Callio Therapeutics (search) has dosed the first patient in a Phase I clinical trial of CLIO-8221 (search), a novel dual-payload antibody-drug conjugate targeting HER2-expressing solid tumors (search).
CLIO-8221 (search) combines a topoisomerase 1 inhibitor (search) with an ATR inhibitor (search) to overcome resistance mechanisms that limit single-payload ADCs.
The Phase I trial is ongoing in Australia and the U.S. with FDA IND clearance, and expansion to China is planned following regulatory review.
Callio Therapeutics (search) has achieved a significant milestone by dosing the first patient in a Phase I clinical trial evaluating CLIO-8221 (search), a first-in-class dual-payload antibody-drug conjugate (ADC) designed to treat advanced HER2-expressing solid tumors (search). The Seattle and Singapore-based biotherapeutics company announced this development alongside receiving IND clearance from the U.S. Food and Drug Administration (search).
Novel Dual-Payload Approach Targets Resistance Mechanisms
CLIO-8221 (search) represents a breakthrough in ADC technology by delivering two mechanistically complementary payloads directly to HER2 (search)-expressing tumors: a topoisomerase 1 (search) (Topo1) inhibitor and an ATR inhibitor (search). This dual-payload strategy addresses a critical limitation of existing HER2-targeted therapies, as most patients eventually progress on treatment despite retaining HER2 expression.
"CLIO-8221 (search) uses a potent combination of two complementary anti-cancer (search) payloads to address a common mechanism that causes resistance to single-payload ADCs," said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer of Callio Therapeutics (search). The company's approach targets mechanistic resistance to cytotoxic payloads, which has emerged as a key reason for treatment failure in current HER2 (search)-targeted therapies.
Compelling Preclinical Data Supports Clinical Development
In preclinical models, CLIO-8221 (search) demonstrated superior anti-tumor activity compared to single-payload ADCs. The dual-payload ADC achieved tumor regression with a single dose in both Topo1 inhibitor-insensitive and refractory models, significantly outperforming existing single-payload approaches.
The mechanism of action involves simultaneous inhibition of Topo1 and blocking of the DNA damage response through ATR inhibition. While Topo1 inhibitors have shown strong clinical activity, activation of the DNA damage response following Topo1 inhibitor-induced replication stress represents a potential major driver of resistance. By combining these complementary mechanisms, CLIO-8221 (search) is engineered to overcome payload insensitivity and sensitize tumors to Topo1 inhibition.
Global Phase I Trial Design and Regulatory Progress
The Phase I clinical trial (NCT07300943) is currently ongoing in Australia and the United States, with Callio Therapeutics (search) having received IND clearance from the FDA in March 2026. The company has also submitted an IND application to the China National Medical Products Administration (search) (NMPA), with trial expansion to multiple Chinese sites expected following regulatory approval.
"Dosing the first patient in the Phase I trial in Australia and receiving IND clearance from the U.S. FDA are significant steps in our commitment to advancing dual-payload ADCs for patients with cancer (search)," said Piers Ingram, Ph.D., Chief Executive Officer of Callio Therapeutics (search). The company achieved this clinical milestone just one year after its launch.
Enhanced Safety Profile Through Advanced Platform Technology
CLIO-8221 (search) incorporates proprietary linker and ADC platform technologies designed to maximize anti-tumor activity while reducing systemic toxicity. Chief Medical Officer Naomi Hunder, M.D., emphasized the potential safety advantages: "Our next-generation linker platform is designed to reduce toxicities, consistent with the broad therapeutic window observed in preclinical studies."
The ADC combines the validated cytotoxic payload exatecan with an ATR inhibitor (search) payload, offering a new potential treatment option for patients whose cancers have become resistant or do not respond to existing Topo1 inhibitor-based ADCs.
Pipeline Expansion Plans
CLIO-8221 (search) represents the first program from Callio Therapeutics (search)' dual-payload ADC pipeline to enter clinical development. The company is actively developing additional dual-payload ADCs featuring rationally designed payload combinations for hard-to-treat tumors, with plans to advance this pipeline into clinical trials in the upcoming months.
The modular and highly adaptable platform features differentiated payload and linker technologies designed to maximize therapeutic benefit while improving tolerability, positioning Callio Therapeutics (search) to rapidly translate ideas into promising drug candidates with the potential to achieve deeper and more durable treatment responses.